Ureter Cancer - Pipeline Review, H1 2017,
provides an overview of the Ureter Cancer (Oncology) pipeline landscape.
Ureter cancer or ureteral cancer is cancer
of the ureter. Symptoms and signs of urethral cancer include bleeding from the
urethra or blood in the urine, discharge from the urethra and enlarged lymph
nodes in the groin area. Risk factors include smoking. Treatment includes
surgery, chemotherapy and radiation therapy.
Report
Highlights
Publisher's Pharmaceutical and Healthcare
latest pipeline guide Ureter Cancer - Pipeline Review, H1 2017, provides
comprehensive information on the therapeutics under development for Ureter
Cancer (Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases.
The Ureter Cancer (Oncology) pipeline guide
also reviews of key players involved in therapeutic development for Ureter
Cancer and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Phase III, Phase II and Phase I stages are
3, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I
stages comprises 1 molecules, respectively.
Ureter Cancer (Oncology) pipeline guide
helps in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built using data
and information sourced from Publisher’s proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ureter Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ureter Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ureter Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ureter Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ureter Cancer (Oncology)
Reasons
to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ureter Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ureter Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 131 pages “Ureter
Cancer - Pipeline Review, H1 2017” report covers Introduction,
Report Coverage, Ureter Cancer - Overview, Ureter Cancer - Therapeutics
Development, Pipeline Overview, Appendix. This report Covered 6 Companies -
Altor BioScience Corp, Eisai Co Ltd, Exelixis Inc, GlaxoSmithKline Plc,
MedImmune LLC, Merck & Co Inc.
Please visit this link for more details: http://mrr.cm/UAS
Related Reports;
Fallopian Tube Cancer - Pipeline Review, H1
2017 - Visit at - http://mrr.cm/UAT
Oropharyngeal Cancer - Pipeline Review, H1
2017 - Visit at - http://mrr.cm/UAq
Find all Oncology Reports
at: http://www.marketresearchreports.com/oncology
No comments:
Post a Comment
Note: only a member of this blog may post a comment.